Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004 ...Middle East

BOSTON and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004 for type 2...

Hence then, the article about eccogene announces us ind approval for glp 1 receptor agonist ecc5004 was published today ( Thursday 03/11/2022 - 08:29 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004 )

Also on site :

• Skanska signs additional contract with existing client to build a data center in USA for USD 228M, about SEK 2.2 billion
• Hawaiian Island May Soon Lose One of Its Beloved Visitor Stops
• Driver dies after plow truck goes off the road in Steuben County